Research
GLP-1 by the numbers
Last updated: November 2026
In published trials, GLP-1 medicines produce average weight loss of roughly 11% to 22.5% of body weight, depending on the drug and the group studied.
GLP-1 Rx Guide gathered the most useful published statistics on GLP-1 results, safety, and use, each with its source, so you can see the evidence behind the class of medicine before you talk to a provider.
How much weight do people lose on GLP-1?
Averages depend on the drug. Drugs.com reports tirzepatide averages up to 22.5% of body weight and semaglutide up to 15% to 21% with certain formulations and doses. In a New England Journal of Medicine trial, people on GLP-1 therapy lost 14.9% on average versus 2.4% on placebo.
Key GLP-1 statistics
| Statistic | What it measures | Source |
|---|---|---|
| Up to 22.5% | Average body weight loss on tirzepatide in trials and meta-analyses | Drugs.com |
| 14.9% vs 2.4% | Average weight loss on GLP-1 therapy vs placebo | New England Journal of Medicine trial |
| 7.03 / 11.07 / 24.15 kg | Weight reduction at 52 weeks for mono-, dual-, and tri-agonists | PubMed Central meta-analysis |
| 10.88% women, 6.78% men | Average weight loss from starting weight in real-world patients | Johns Hopkins Bloomberg School of Public Health, 2026 |
| 26% lower risk | Major adverse cardiovascular events in the SUSTAIN-6 trial | SUSTAIN-6 trial |
| 11% of U.S. adults | Currently take a GLP-1 for weight loss in 2026, up from 3% in 2024 | Gallup |
| 90% of U.S. adults | Aware of GLP-1 drugs for weight loss, up from 80% in 2024 | Gallup |
What these numbers mean for you
The research case for the GLP-1 class is strong: large, repeated trials show meaningful average weight loss, and Johns Hopkins found the drugs comparably effective across age, race, and starting weight. Averages are not promises, though. Results depend on dose, consistency, diet, and how well you tolerate the medicine, which is why a provider review and ongoing check-ins matter.
Common questions
Which GLP-1 is best for weight loss?
In published trials, tirzepatide (Mounjaro, Zepbound) shows the largest average weight loss, up to 22.5% of body weight according to Drugs.com, with semaglutide close behind. The best GLP-1 for you is the one your provider judges safe for your health history, that you can afford every month, and that you can stay on.
More answers in the full GLP-1 FAQWhat is the strongest GLP-1 on the market?
Among approved medicines, tirzepatide currently produces the largest average weight loss in trials. A 2025 meta-analysis on PubMed Central found tri-agonist drugs still in research produced even larger losses at 52 weeks, 24.15 kg on average. Stronger is not always better: higher effect can come with more stomach side effects.
More answers in the full GLP-1 FAQHow long will it take to lose 20 lbs on Wegovy?
It varies widely. In the trial reported in the New England Journal of Medicine, participants on semaglutide lost an average of 14.9% of body weight over 68 weeks. For a 200-pound adult that is about 30 pounds over that period, but your timeline depends on dose, diet, and response.
More answers in the full GLP-1 FAQWhich GLP-1 is best for cardiovascular benefit?
Semaglutide has the longest track record here. In the SUSTAIN-6 trial, it was associated with a 26% reduction in major adverse cardiovascular events, including heart attack and stroke. If heart health is a priority, ask your provider which medicine and which evidence apply to your situation.
More answers in the full GLP-1 FAQHas anyone kept weight off after stopping GLP-1?
Some people do, but many regain weight after stopping. Johns Hopkins researchers note the drugs generally need to be continued to maintain weight loss. If you plan to stop, make a plan with your provider for tapering, nutrition, and activity.
More answers in the full GLP-1 FAQSources
- Drugs.com: Which GLP-1 drug is best for weight loss?
- PubMed Central: Comparative efficacy and safety of GLP-1 receptor agonists
- Johns Hopkins Bloomberg School of Public Health (2026)
- Gallup: In U.S., GLP-1 usage reaches new high
- Side Effects and Safety Profile of GLP-1 Receptor Agonists (NEJM and SUSTAIN-6 figures)